Clinical Trials Browser

Interventional × Adenocarcinoma × pembrolizumab × Clear all

Adenocarcinoma, Neoplasms

NCT04222972 2026-03-05

AcceleRET-Lung

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06561685 2026-02-10

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2 Not yet recruiting

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

15 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Recruiting

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

209 enrolled

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07018570 2025-08-26

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

26 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT04069273 2025-07-31

SEQUEL

Phase 2 Recruiting

58 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Phase EARLY_PHASE1 Completed

11 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Phase 1 Active not recruiting

48 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

106 enrolled

GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06532799 2024-11-12

BAH250

Phase 1/2 Recruiting

75 enrolled

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03664024 2024-08-22

KEYNOTE-782

Phase 2 Completed

118 enrolled 14 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT05101356 2024-05-21

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Phase 1/2 Recruiting

77 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

NCT03861793 2024-03-05

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Phase 1/2 Completed

116 enrolled

GastrointestinalThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Stomach Neoplasms

NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Phase 2 Terminated

3 enrolled 10 charts

Tumor-Agnostic

Adenocarcinoma

NCT02918162 2024-02-15

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Phase 2 Completed

49 enrolled 10 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03488667 2023-05-19

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

5 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT04699071 2021-10-21

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Phase 2 Unknown

10 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT02346955 2020-08-27

MK-6018-001

Phase 1 Terminated

27 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03407976 2020-07-15

APPEASE

Phase 1 Terminated

5 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Transitional Cell

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2 Unknown

35 enrolled

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02943603 2018-07-13

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Clinical Trials

LUCERNA

AcceleRET-Lung

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

DG-03

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Cabozantinib and Pembrolizumab in Metastatic Pancreas

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

SEQUEL

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

A Study of NDI 1150-101 in Patients With Solid Tumors

BAH250

KEYNOTE-782

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

MK-6018-001

APPEASE

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach